AU · rank #13 · 2026-07-24
MGTX
NASDAQ · $1.16B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.286 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.121 |
| Analyst upside Consensus target $28.38 | +134.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +19.69% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.60 |
| Gross margin TTM | +95.4% |
| 52w high | $15.35 |
| Market cap (USD) | $1.16B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
MeiraGTx Holdings PLC (MGTX) is a clinical-stage gene therapy company advancing late-stage programs in xerostomia, inherited retinal disease, and congenital blindness with a vertically integrated manufacturing platform.
Rationale
The quant signal is reinforced by very high analyst upside, strongly positive ratings, unanimous revision agreement, improving momentum, and recent financing/collaboration news that de-risks execution through the next regulatory catalysts.
Material risks
- 1A clinical or regulatory miss in AAV2-hAQP1, bota-vec, or AAV-AIPL1 would hit the core value drivers at once and could leave the stock with little support beyond sentiment.
- 2The Oberland royalty financing and other structured capital raises cap future economics and, with limited commercial revenue visibility, can pressure upside if launch timing slips or reimbursement is weaker than expected.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.